Drugs / EYE103
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05919693 | Jun 2023 → Aug 2024 | age-related macular degeneration, diabetic macular edema | EyeBiotech Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07205887 | Sep 2025 → Jun 2028 expected | age-related macular degeneration, occlusion of tributary of retinal vein | EyeBiotech Ltd. | Recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06957080 | Apr 2025 → Mar 2027 expected | diabetic macular edema | EyeBiotech Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06571045 | Aug 2024 → Sep 2026 expected | diabetic macular edema | EyeBiotech Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYE103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06571045 ↗ |
| Route | Intravitreal | “formulated for IVT administration” NCT05919693 ↗ |